SCHEMBL1056828

SCHEMBL1056828

CCc1nc2c(I)ccnc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.41
ADORA1 P30542 3/20 0.41
ADORA2A P29274 2/20 0.41
DDAH1 O94760 1/20 0.37
GSK3A P49840 9/20 0.36
GSK3B P49841 9/20 0.36
CDK1 P06493 7/20 0.36
CDK5 Q00535 6/20 0.36
MAPK8 P45983 3/20 0.36
AURKA O14965 2/20 0.36
MAP4K4 O95819 2/20 0.36
PAK4 O96013 2/20 0.36
ABL1 P00519 2/20 0.36
FYN P06241 2/20 0.36
RET P07949 2/20 0.36
KDR P35968 2/20 0.36
CDK8 P49336 2/20 0.36
ACVR1 Q04771 2/20 0.36
PTK2 Q05397 2/20 0.36
LRRK2 Q5S007 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20197285 0.88 GSK3A (0.42) ADORA3ADORA1ADORA2AGSK3AGSK3B
SCHEMBL4370028 0.82 ADORA1 (0.41) ADORA3ADORA1ADORA2ADDAH1GSK3A
SCHEMBL4371769 0.81 GAA (0.41) ADORA3ADORA1ADORA2ADDAH1GSK3A
SCHEMBL1080357 0.78 CCNB2 (0.40) GSK3AGSK3BCDK1CDK5CCNB2
SCHEMBL24422924 0.78 ADORA3 (0.38) ADORA3ADORA1ADORA2ADDAH1GSK3A
SCHEMBL1058944 0.76 CCNB2 (0.38) ADORA3GSK3AGSK3BCDK1CDK5
SCHEMBL15925247 0.74 DAO (0.39) AURKAAURKBPDE3BPDE3A
SCHEMBL4295424 0.73 NOS2 (0.58) GSK3AGSK3BCDK1CDK5CDK2
SCHEMBL4370037 0.72 NOS2 (0.41) GSK3AGSK3BCDK1CDK5MAPK8
SCHEMBL32671116 0.72 MAPK14 (0.35) GSK3AGSK3BCDK1CDK5CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8691814-B2 Deazapurines and uses thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-04-08 US disclosed
US-20110105427-A1 DEAZAPURINES AND USES THEREOF DAUN JANE 2011-05-05 US disclosed
US-7868002-B2 Deazapurines and uses thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-01-11 US disclosed
EP-1474425-B9 DEAZAPURINES AND USES THEREOF EISAI CO LTD (JP) 2008-07-02 EP disclosed
US-20080103137-A1 Deazapurines and uses thereof EISAI CO., LTD. 2008-05-01 US disclosed
US-7314936-B2 Deazapurines and uses thereof EISAI CO., LTD. (JP) 2008-01-01 US disclosed
EP-1707566-A1 Deazapurines and uses thereof Eisai Co., Ltd. (JP) 2006-10-04 EP disclosed
EP-1474425-B1 DEAZAPURINES AND USES THEREOF EISAI CO LTD (JP) 2006-05-24 EP disclosed
US-20050124649-A1 Deazapurines and uses thereof EISAI CO., LTD (JP) 2005-06-09 US disclosed
US-20040186127-A1 Novel deazapurines and uses thereof EISAI CO., LTD. (JP) 2004-09-23 US disclosed
WO-2004063336-A2 USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS EISAI CO. LTD. (JP) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105427-A1 DEAZAPURINES AND USES THEREOF TPMT, CD38, CD2 ADORA3 54/4885ADORA1 50/4885ADORA2A 18/4885
US-20050124649-A1 Deazapurines and uses thereof TPMT, CD38, CD2 ADORA3 55/4885ADORA1 51/4885ADORA2A 18/4885
US-20080103137-A1 Deazapurines and uses thereof TPMT, TYMP, ENTPD5 ADORA3 455/4885ADORA1 508/4885ADORA2A 125/4885
US-20040186127-A1 Novel deazapurines and uses thereof TPMT, ENTPD5, MTAP ADORA3 30/4885ADORA1 36/4885ADORA2A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.